The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today announces that it will be presenting brand-new data on ...
When the Precision Medicine Initiative was launched in 2015, it completely transformed patient care in oncology. Now, individual differences in genetics, environment and lifestyle, along with the ...
Twist Bioscience Corporation, a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced ...
Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Association of ...
Highly sensitive and efficient analysis with an emphasis on specific regions of the genome. epicGEN NGS panels are designed for modern diagnostic laboratories. The epicGEN Solid Cancer & MSI Kit ...
Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa These findings ...
According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback